Mallinckrodt (Mallinckrodt) Total Liabilities : $2,538 Mil (As of Mar. 2024)

View and export this data going back to 2022. Start your Free Trial

What is Mallinckrodt Total Liabilities?

Mallinckrodt's Total Liabilities for the quarter that ended in Mar. 2024 was $2,538 Mil.

Mallinckrodt's quarterly Total Liabilities increased from Jun. 2023 ($4,481.50 Mil) to Sep. 2023 ($5,892.90 Mil) but then declined from Sep. 2023 ($5,892.90 Mil) to Mar. 2024 ($2,537.70 Mil).

Mallinckrodt's annual Total Liabilities declined from Dec. 2020 ($8,696.20 Mil) to Dec. 2021 ($8,602.90 Mil) and declined from Dec. 2021 ($8,602.90 Mil) to Dec. 2022 ($4,400.10 Mil).

Mallinckrodt Total Liabilities Historical Data

The historical data trend for Mallinckrodt's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Mallinckrodt Total Liabilities Chart

Mallinckrodt Annual Data

Trend

Sep13

Sep14

Sep15

Sep16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Total Liabilities

Get a 7-Day Free Trial

7,990.00

8,398.20

8,696.20

8,602.90

4,400.10

Mallinckrodt Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Mar24
Total Liabilities	Get a 7-Day Free Trial															4,400.10	4,406.40	4,481.50	5,892.90	2,537.70

Mallinckrodt Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Mallinckrodt's Total Liabilities for the fiscal year that ended in Dec. 2022 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	743.8	+	(3027.7	+	587.3
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0.3	+	41)
	=	4,400

Total Liabilities	=	Total Assets (A: Dec. 2022 )	-	Total Equity (A: Dec. 2022 )
	=	6013.8	-	1613.7
	=	4,400

Mallinckrodt's Total Liabilities for the quarter that ended in Mar. 2024 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	476	+	(1747.9	+	273.7
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0	+	40.1)
	=	2,538

Total Liabilities	=	Total Assets (Q: Mar. 2024 )	-	Total Equity (Q: Mar. 2024 )
	=	3629.6	-	1091.9
	=	2,538

Mallinckrodt Total Liabilities Related Terms

Thank you for viewing the detailed overview of Mallinckrodt's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Mallinckrodt (Mallinckrodt) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Mallinckrodt PLC (OTCPK:MCKPF) » Definitions » Total Liabilities

Comparable Companies

Traded in Other Exchanges

N/A

Address

College Business and Technology Park, Cruiserath, Blanchardstown, Dublin, IRL, 15

Website

https://www.mallinckrodt.com

Mallinckrodt PLC develops, manufactures, markets, and distributes specialty pharmaceutical products and therapies. Its areas of focus include autoimmune and rare diseases in specialty areas like neurology, rheumatology, nephrology, pulmonology and ophthalmology; immunotherapy and neonatal respiratory critical care therapies; analgesics and gastrointestinal products. The company operates its business in two reportable segments namely Specialty Brands which include specialty pharmaceutical brands; and Specialty Generics which includes niche specialty generic drugs and active pharmaceutical ingredients. It generates maximum revenue from the Specialty Brands segment. Geographically, it derives a majority of its revenue from the United States.

Executives

Alta Fundamental Advisers Llc	10 percent owner	1500 BROADWAY, SUITE 704, NEW YORK NY 10036
Jason Daniel Goodson	officer: EVP & Head of Corp Development	106 CENTRAL PARK AVENUE, WENTZVILLE MO 63885
James R Sulat	director
Paul Bisaro	director
Sigurdur O Olafsson	director, officer: President and CEO	360 MOUNT KEMBLE AVENUE, MORRISTOWN NJ 07960
Stephen Andrew Welch	officer: EVP & Head of Spec Generics	18440 BRIDGEMORE LANE, LOUISVILLE KY 40245
Peter C Richardson	officer: EVP & Chief Scientific Officer	28903 NORTH AVENUE PAINE, VALENCIA CA 91355
Susan Michele Silbermann	director	C/O LIANBIO, 103 CARNEGIE CENTER DRIVE, SUITE 215, PRINCETON NJ 08540
Lisa French	officer: EVP & Chief Commercial Officer	301 CONTINENTAL LANE, PAOLI PA 19301
Mark Anthony Tyndall	officer: EVP & Chief Legal Offi & Secre	1101 Q ST NW, WASHINGTON DC 20009
Henriette Nielsen	officer: EVP & Chief Transformation OFC	202 WEST 85TH STREET, APT. 5, NEW YORK NY 10024
Karen Ling	director	C/O FOREST LABORATORIES, INC., 909 THIRD AVENUE, NEW YORK NY 10022
Anne Clem Whitaker	director	109 BRIERY BRANCH COURT, MORRISVILLE NC 27560
Olifant Luxco S.a R.l.	10 percent owner	19, RUE DE BITBOURG, LUXEMBOURG N4 L-1273
Paul Rutherford Carter	director	SOUTH BUILDING, 2 ROUNDWOOD AVENUE, STOCKLEY PARK X0 UB11 1AF